US panel endorses Allergan's Latisse for eyelash growth
This article was originally published in Scrip
Executive Summary
Allergan's glaucoma drug bimatoprost is primed to add an eyelash growth indication in the US following an FDAadvisory panel's unanimous endorsement on December 5th. However, the experts recommended the company conduct postmarketing studies of long-term safety, use by chemotherapy patients and teenagers.